Pharvaris N.V.
PHVS
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.5B
$35.17
▲ +0.69%
P/E
-11.16
Mkt Cap
$2.5B
52-Wk Range
$20.65–$38.13
52-Week Range
$20.65 - $38.13
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 60.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta -2.3).
Growth
Stable outlook
Value
Deep value opportunity - significant discount to sector peers
Momentum
Strong
+16.7% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying PHVS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 12, 2026
Reported EPS of -$0.81 vs -$0.75 consensus (-8.5% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-8.5%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
9 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 14, 2026
vs Industry
How PHVS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.